3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
36
Neoplasm Metastasis
8
Ovarian Neoplasms
5
Sarcoma
4
Neoplasms
4
Lymphoma, Non-Hodgkin
4
Pancreatic Neoplasms
3
Multiple Myeloma
3
Lymphoma
3
Glioma
3
Endometrial Neoplasms
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms by Site
2
Medulloblastoma
2
Lymphoma, Mantle-Cell
2
Lung Neoplasms
2
Liposarcoma
2
Histiocytosis, Langerhans-Cell
2
Hereditary Sensory and Autonomic Neuropathies
2
Interventions
durvalumab
3
abemaciclib
3
Fulvestrant
3
Cisplatin
3
ribociclib
2
pembrolizumab
2
palbociclib
2
Pemetrexed
2
Nivolumab
2
Letrozole
2
Carboplatin
2
Bevacizumab
2
Anastrozole
2
130-nm albumin-bound paclitaxel
2
selpercatinib
1
selinexor
1
repotrectinib
1
relatlimab
1
relacorilant
1
olaparib
1
gallium 68 PSMA-11
1
exemestane
1
enfortumab vedotin
1
elacestrant
1
darolutamide
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
Sunitinib
1
STX-478
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
palbociclib
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled